Supply Chain Intelligence

Minerva Neurosciences, Inc. Supply Chain

NERV supply chain intelligence for Minerva Neurosciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

NERV ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

2Suppliers
6Customers
3Debt Items
20Related Chains

Minerva Neurosciences, Inc. Suppliers

TickerNameConfidenceEvidence
MTPC MTPC 92% We have entered into a license agreement with MTPC dated as of August 30, 2007, as amended
TANABE-PHARMA-CORPORATION TANABE-PHARMA-CORPORATION 90% We will pay Tanabe Pharma a tiered royalty for net sales of product by us or any of our affiliates or sublicensees containing the licensed compound

Minerva Neurosciences, Inc. Customers

TickerNameConfidenceEvidence
JANSSEN JANSSEN 90% We have only generated collaborative revenue due to opting out of our license and co-development agreement with Janssen.
SNYNF Sanofi 72% ms represent a significant debilitating, unmet need; 6 • Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current product candidate portfolio, par…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from NERV graph: ms represent a significant debilitating, unmet need; 6 • Selectively explore collaborations with leading pharmaceuti…
CYRENAIC-PHARMACEUTICALS-INC CYRENAIC-PHARMACEUTICALS-INC 62% ms represent a significant debilitating, unmet need; 6 • Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current product candidate portfolio, par…
LUYE-PHARMA-GROUP LUYE-PHARMA-GROUP 62% ms represent a significant debilitating, unmet need; 6 • Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current product candidate portfolio, par…
MITSUBISHI-TANABE-PHARMA-CORPORATION MITSUBISHI-TANABE-PHARMA-CORPORATION 62% ms represent a significant debilitating, unmet need; 6 • Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current product candidate portfolio, par…

Minerva Neurosciences, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
NERV-DEBT Debt stack $60.0M 90% Market cache reports total debt of $60.0M.
NERV-DEBT-11220 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
NERV-DEBT-11219 Warrants outstanding: 166344 90% xbrl warrant detail from xbrl 2025-12-31.

Minerva Neurosciences, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Minerva Neurosciences, Inc..

Minerva Neurosciences, Inc. Ownership

HolderNameConfidenceEvidence
NERV-OWNER-VIVO-CAPITAL-LLC Vivo Capital, LLC 90% 13F overlay lists Vivo Capital, LLC as top holder; 44 tracked holders.

Minerva Neurosciences, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BNRG Brenmiller Energy Ltd 100.00 2
AZN AstraZeneca PLC 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
BLLN BillionToOne, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
AORT Artivion, Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
CSTE Caesarstone Ltd. 100.00 2
View NERV supply chain intel →

Explore the full interactive supply chain map for Minerva Neurosciences, Inc..

Open NERV supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map